OpenScience.ink

2 weeks ago • European journal of preventive cardiology

Health outcomes in people with diabetes, heart artery disease, and heart failure treated with tirzepatide or dulaglutideOutcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.

🥉 Top 5% JournalArticle

3 weeks ago • Frontiers in medicine

Different eye safety effects of glucagon-like peptide-1 receptor drugs based on their chemical differencesDivergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework.

📖 Top 20% JournalArticle

3 weeks ago • Frontiers in medicine

GLP-1 receptor agonists for fatty liver disease linked to metabolic problems: plan for a review of clinical trialsGLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials.

📖 Top 20% JournalArticle

3 weeks ago • Frontiers in endocrinology

Pancreatic and bile duct safety concerns linked to GLP-1 receptor agonists and tirzepatide based on FDA report analysisPancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reports.

🎖️ Top 10% JournalArticle

3 weeks ago • Frontiers in endocrinology

Continuous glucose levels after stopping diabetes-related weight loss drugs: clues about metabolism and keeping weight offContinuous glucose monitoring after discontinuation of incretin-based obesity pharmacotherapy: indirect evidence and a research framework for metabolic stability and weight maintenance.

🎖️ Top 10% JournalArticle

3 weeks ago • Aesthetic plastic surgery

Facial Changes Linked to GLP-1 Receptor Agonists Beyond Their Weight Loss EffectsBeyond Weight Loss: Facial Remodeling Associated with GLP-1 Receptor Agonists-A Systematic Review and Therapeutic Framework.

📖 Top 20% JournalArticle

3 weeks ago • Annals of clinical and translational neurology

How Diabetes May Cause Thinking Problems and New Treatment ApproachesDiabetes-Associated Cognitive Impairment: Pathophysiology and Emerging Therapies.

🎖️ Top 10% JournalArticle

3 weeks ago • Annals of clinical and translational neurology

Effects of Glucagon-Like Peptide-1 Receptor Activators in Multiple Sclerosis: A Focused ReviewGlucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review.

🎖️ Top 10% JournalArticle

3 weeks ago • Frontiers in endocrinology

🎖️ Top 10% JournalArticle

3 weeks ago • The Journal of clinical endocrinology and metabolism

Incretin treatment before pregnancy may lower pregnancy problems and heart-related risks in polycystic ovary syndromePreconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome.

🥉 Top 5% JournalArticle

3 weeks ago • HSS journal : the musculoskeletal journal of Hospital for Special Surgery

Use of GLP-1 Receptor Agonists Linked to Lower Early Hip Replacement Revision Risk Compared to Weight-Loss SurgeryGLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study.

📖 Top 30% JournalArticle

3 weeks ago • ACS omega

Finding New Peptides That May Block DPP-IV Using Computer Models and Early Lab TestsDiscovery of Novel Peptides as DPP-IV Inhibitors: In Silico Screening, Molecular Dynamics Simulations, and Preliminary In Vitro Evaluation.

📖 Top 30% JournalArticle

3 weeks ago • Frontiers in pharmacology

Comparing SGLT2 inhibitors, semaglutide, and finerenone for diabetic kidney disease using network analysisSGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis.

📖 Top 20% JournalArticle

3 weeks ago • Frontiers in pharmacology

Tirzepatide compared to other diabetes medicines for preventing foot problems in type 2 diabetesTirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes.

📖 Top 20% JournalArticle

3 weeks ago • ACS omega

A Peptide Blocking PTPN1/N2 Proteins Improves Long-Lasting Blood Sugar Control and Weight Loss in MiceThe PTPN1/N2 Peptide Inhibitor Achieves Potent, Long-Acting Glycemic Control and Weight-Loss Dual Efficacy in Mice.

📖 Top 30% JournalArticle

3 weeks ago • Journal of internal medicine

Serious side effects of GLP-1 receptor drugs: what is known, uncertain, and important for treatmentGLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications.

🥉 Top 5% JournalArticle

3 weeks ago • Clinical kidney journal

Communication between the gut and kidneys is reduced in people with type 2 diabetesGut-kidney signaling is impaired in individuals with type 2 diabetes.

🎖️ Top 10% JournalArticle

3 weeks ago • Obesity (Silver Spring, Md.)

Cost-Effectiveness and Fairness of Using Semaglutide to Treat ObesityThe Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment.

🎖️ Top 10% JournalArticle

3 weeks ago • Frontiers in pharmacology

Pasteurized Akkermansia muciniphila as a potential treatment affecting multiple functions in the gut-liver system: current evidence, unclear cause-and-effect, and research prioritiesPasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities.

📖 Top 20% JournalArticle

3 weeks ago • Frontiers in public health

Adults' understanding, opinions, information sources, and use of weight-loss injections in Al-Ahsa, Saudi ArabiaKnowledge, attitudes, information sources, and use of weight-loss injections among adults in Al-Ahsa, Saudi Arabia: a cross-sectional study.

📖 Top 20% JournalArticle

3 weeks ago • Current heart failure reports

Exercise, Diet, and GLP-1 Medicines to Improve Weight and Muscle Strength in Heart Failure with Normal PumpingExercise, Nutrition and GLP-1 Medicines to Improve Body Weight and Muscle Function in Heart Failure with Preserved Ejection Fraction.

🎖️ Top 10% JournalArticle

3 weeks ago • Frontiers in pharmacology

Modeling how exposure to efpeglenatide builds tolerance to nausea and vomiting over time to guide dose increasesExposure-driven tolerance modeling of efpeglenatide-induced nausea or vomiting using repeated time-to-event analysis: implications for dose-escalation strategies.

📖 Top 20% JournalArticle

3 weeks ago • Frontiers in endocrinology

Liraglutide's effects on blood sugar and metabolism in congenital generalized lipodystrophyLiraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes.

🎖️ Top 10% JournalArticle

4 weeks ago • Clinical and translational gastroenterology

US Healthcare Professionals' Management of Fatty Liver Disease and Knowledge of Hormone-Based Diabetes TreatmentsUS Healthcare Professionals' Management of MASH and Knowledge of GLP-1, GIP, and Glucagon Receptor Agonists.

📖 Top 20% JournalArticle

4 weeks ago • European heart journal

Semaglutide reduces heart and liver changes in heart failure with preserved pumping strength, independent of weight lossSemaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction.

🥇 Top 1% JournalArticle

4 weeks ago • Pharmacology research & perspectives

How Glucagon-Like Peptide-1 Drugs May Influence Blood Pressure and Heart HealthGlucagon-Like Peptide-1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications.

📖 Top 30% JournalArticle

1 month ago • BJOG : an international journal of obstetrics and gynaecology

Effects of Glucagon-Like Peptide-1 Receptor Drugs During Early Pregnancy on Birth OutcomesGlucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Periconception Exposure and Perinatal Outcomes.

🎖️ Top 10% JournalArticle

2 weeks ago • European heart journal. Case reports

Heart rhythm problem improving after weight-loss drug semaglutide started in a resistant case of irregular heartbeatCardiometabolic therapy for rhythm control: a case report of refractory atrial fibrillation resolving after initiation of semaglutide for obesity.

Case Reports

1 week ago • Hormone research in paediatrics

Semaglutide treatment in two very young children with severe early obesitySEMAGLUTIDE TREATMENT IN TWO VERY YOUNG CHILDREN WITH SEVERE EARLY-ONSET OBESITY.

📖 Top 20% JournalCase Reports

3 weeks ago • Obesity facts

Weight changes from GLP-1RA treatment in patients with PCSK1 gene mutations – two case reportsGLP-1RA based treatment in patients with a PCSK1 mutation has profound effects on body weight - two case reports.

🎖️ Top 10% JournalCase Reports

← prevpage 4 of 16next →

GLP-1 Therapies Research Papers